Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 7/20 | 0.45 |
| ▸ | NPC1 | O15118 | 5/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20020162 | 0.83 | MEN1 (0.73) | MEN1KMT2AALDH1A1RAB9ANPC1 | |
| SCHEMBL10938471 | 0.81 | MEN1 (0.59) | MEN1KMT2AALDH1A1RAB9ANPC1 | |
| SCHEMBL20020236 | 0.81 | MEN1 (0.59) | MEN1KMT2AALDH1A1RAB9ANPC1 | |
| SCHEMBL6741466 | 0.79 | RAB9A (0.41) | MEN1KMT2ARAB9ANPC1L3MBTL1 | |
| SCHEMBL9500113 | 0.78 | MEN1 (0.65) | MEN1KMT2AALDH1A1RAB9ANPC1 | |
| SCHEMBL6741453 | 0.76 | RAB9A (0.81) | MEN1KMT2ARAB9ANPC1L3MBTL1 | |
| SCHEMBL10938868 | 0.75 | MEN1 (0.52) | MEN1KMT2AALDH1A1RAB9ANPC1 | |
| SCHEMBL9366576 | 0.75 | MEN1 (0.52) | MEN1KMT2AALDH1A1RAB9ANPC1 | |
| SCHEMBL2104797 | 0.74 | ACACB (0.46) | ALDH1A1RAB9ANPC1SMN1; SMN2TDP1 | |
| SCHEMBL6743168 | 0.74 | RAB9A (0.71) | MEN1KMT2ARAB9ANPC1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1689393-A4 | PREPARATION OF 1,7-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2008-12-17 | — | — | EP | disclosed |
| US-20070123561-A1 | Preparation of 1,7-disubstituted azabensimidazoles as kinase inhibitors | LEE DENNIS | 2007-05-31 | — | — | US | disclosed |
| EP-1689393-A2 | PREPARATION OF 1,7-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005037198-A2 | PREPARATION OF 1,7-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123561-A1 | Preparation of 1,7-disubstituted azabensimidazoles as kinase inhibitors | TNK2, CDC42BPB, CDC42BPA | MEN1 2126/4885KMT2A 2508/4885ALDH1A1 4114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.